Search Results 931-940 of 17980 for sickle cell
Mayo Clinic's pioneering approach to biotherapeutics is in the spotlight at a national biotech conference aimed at bringing new life-saving cell and gene ...
Preparing to biomanufacture a new CAR-T cell therapy for B-cell cancers featured. Research. Preparing to biomanufacture a new CAR-T cell therapy for B-cell ...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
This clinical study further documented lower death and hospitalization rates among those treated with cell therapy. This research is published in Stem Cells ...
Antibody-drug conjugates are targeted cancer therapies. They deliver potent drugs directly into cancer cells while minimizing harm to healthy tissue. These ...
Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may ...
Rochester, Minn., Scottsdale/Phoenix, Ariz. This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies ...
... cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486 ...
Rochester, Minn. The purpose of this study is to monitor T cell responses from patients with advanced cancer who are being treated with an anti-PD (programmed ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.